Episode Details
Back to EpisodesJacob Sands, MD / Raffaele Califano, MD - Novel ADC Targets in Advanced NSCLC: Examining Emerging Strategies for TROP2-Directed ADCs
Published 1 year, 10 months ago
Description
Please visit answersincme.com/93496951-replay1 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, experts in NSCLC discuss the significance of the latest data for TROP2-directed ADCs in NSCLC. Upon completion of this activity, participants should be better able to: Explain the rationale for antibody drug conjugates (ADCs) in the treatment of advanced non-small cell lung cancer (NSCLC); Identify the latest efficacy and safety data for ADCs in advanced NSCLC; and Recognize key clinical factors to optimize the evidence-based use of current and emerging ADCs in advanced NSCLC.